Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets

Human Psychopharmacology

Volumn 22, Issue 5, 2007, Pages 307-314

  Chue, Pierre ^a,c   Prinzo, Rosanna S ^b   Binder, Carin E ^b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b Janssen Ortho Inc   (Canada)

^c NONE   (Canada)

Author keywords

Antipsychotic; CGI Severity; Maintenance of effect; Orally disintegrating risperidone tablets; Transition

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERDAL M TABS; RISPERIDONE; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; ADULT; AGED; AGITATION; ANXIETY; ARTHRALGIA; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; DEMENTIA; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUBILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INSOMNIA; JOINT SWELLING; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NOSE CONGESTION; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE RATE; REFERENCE VALUE; RESPIRATORY TRACT INFECTION; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SORE THROAT; SYSTOLIC BLOOD PRESSURE; TABLET COMPRESSION; TABLET DISINTEGRATION; THORAX PAIN; WEIGHT CHANGE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; RISPERIDONE; SOLUBILITY; TABLETS;

EID: 34547524961     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.852     Document Type: Article

References (35)

1. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, mundo E. 2003. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63: 493-512.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Press: Washington (DC).
3. Bachert C, El-Akkad T. 2002. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89(3): 292-297.
4. Andreasen BF, Damsgaard EMS. 2001. Drug therapy in the elderly: what doctors believe and patients actually do. Brit J Clin Pharmacology 51: 615.
5. Chue P, Welch R, Binder C. 2004. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can J Psych 49(10): 701-703.
6. Chue P, Jones B, Taylor CC, Dickson R. 2002. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry 47(8): 771-774.
7. Chue P. 2004. Compliance and convenience; do physicians and patients see depot medication differently? Acta Neuropsychiatrica 16: 314-338.
8. Clark LT, Afflu E. 1995. Antihypertensive therapy: factors affecting medication compliance and blood pressure control. Amer J of Managed Care 1(3): 289-294.
9. Collantes E, Cutis P, Wing Lee K, et al. 2002. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Prac 3: 1-10.
10. Cramer J, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49: 196-201.
11. Dolder CR, Lacro JP, Leckband S, Jeste DV. 2003. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 23(4): 389-399.
12. Donohue G, Owens N, O'Donnell C, et al. 2001. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 16(5): 293-298.
13. Fleischhacker WW, Oehl MA, Hummer M. 2003. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 64: 10-13.
14. Guy W (ed.). 1976. ECDEU Assessment Manual for Psychopharmacology, revised. US National Institute of Mental Health; DHEW Pub. No. (ADM) 76, Rockville, MD.
15. James PN, Anderson JB, Prior JG, White JP, Henry JA, Cochrane GM. 1985. Patterns of drug taking in patients with chronic airflow obstruction. Postgrad Med J 61: 7-10.
16. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
17. Hamilton MC. 1976. In ECDEU Assessment Manual for Psychopharmacology, Guy W (ed.). Revised. U.S. National Institute of Health: Rockville, MD; 193-197.
18. Kay R, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2): 261-276.
19. Keith S. 2006. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 30(6): 996-1008.
20. Kelleher JP, Centorrino F, Albert MJ, Baldessarinin RJ. 2002. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 16(4): 249-261.
21. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. 2003. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia, Int J Neuropsychopharmacol 6(2): 97-102.
22. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. 2002 Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psych 63(10): 892-909.
23. Leucht S, Heres S. 2006. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psych 67(5): 3-8.
24. Leucht S, Engel RR. 2006. The relative sensitivity of the clinical global impressions scale and the brief psychiatric rating scale in antipsychotic drug trials. Neuropsychopharmacology 31: 406-412.
25. Leucht S, Kane J, Etschel E, Kissling W, Hamann J, Engel RR. 2006. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31(10): 2318-2325.
26. Likert R. 1932. A technique for the measurement of attitudes. Arch Psychol 140: 1-55.
27. Lingam R, Scott J. 2002. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105(3): 164-172.
28. Masand PS. 2003. Tolerability and adherence issues in antidepressant therapy. Clin Therapeutics 25(8): 2289-2304.
29. Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. 2006. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry 39(6): 209-212.
30. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
31. Perkins DO. 2002. Predictors of noncompliance in patients with schizophrenia. J Clin Psych 63(12): 1121-1128.
32. Rabinowitz J, Mehnert A, Eerdekens M. 2006. To what extent do the PANSS and CGI-S overlap? J Clin Psychopharmacol 26(3): 303-307.
33. Van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. 2003. Pharmacokinetic comparison of fastdisintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Therapeutics 25: 1687-1699.
34. Veldhuyzen Van Zanten SJO, Chiba N, Armstrong D, et al. 2006. Validation of a 7-point global overall symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther 23(4): 521-529.
35. Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR. 2003. Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder. Psychol Med 33: 611-622.